937276-27-2

Upstream product

• 937276-26-1 N^α-(benzyloxycarbonyl)-N^β-(tert-butoxycarbonyl)-N^β-(2-hydroxyethyl)hydrazide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114897-60-8 N^β-(tert-butoxycarbonyl)-N^β-(2-hydroxyethyl)hydrazide 

Downstream Products

• 937276-24-9 methyl N-[2-(N^α-benzyloxycarbonyl-N^β-tert-butoxycarbonyl-hydrazino)ethyl]glycinate 
• 937276-19-2 methyl N-[2-(N^α-benzyloxycarbonyl-N^β-tert-butoxycarbonyl-hydrazino)ethyl]-N-{[4-N-(benzyloxycarbonyl)cytosin-1-yl]acetyl}glycinate 
• 937276-32-9 N-[2-(N^α-benzyloxycarbonyl-N^β-tert-butoxycarbonylhydrazino)ethyl]-N-[(thymin-1-yl)acetyl]glycine 
• 937276-18-1 methyl N-[2-(N^α-benzyloxycarbonyl-N^β-tert-butoxycarbonyl-hydrazino)ethyl]-N-[(thymin-1-yl)acetyl]glycinate 
• 937276-29-4 methyl N-[2-[2-(N^α-benzyloxycarbonyl-N^β-tert-butoxycarbonyl-hydrazino)ethyl]-N-[(thymin-1-yl)acetyl]glycyl]aminoethyl-N-[(thymin-1-yl)acetyl]glycinate 

Relevant academic research and scientific papers

A short stereoselective synthesis of (+)-aza-galacto-fagomine (AGF)

A catalytic asymmetric synthesis of (+)-aza-galacto-fagomine (AGF) – the most promising compound for the pharmacological chaperone therapy of Krabbe disease – was accomplished in six steps, in 14% overall yield. The synthesis hinges on the combination of

Synthesis of hydrazino-peptide nucleic acid monomers and dimers as new PNA backbone building blocks

We describe the synthesis of new hydrazinoPNA (hydPNA) monomers and new hydPNA-containing dimers. For the hydPNA monomers, the primary terminal amino group of the aminoethylglycine unit of classical aegPNA is replaced by a hydrazine moiety. An appropriate